Wan Fengyi and the Quiet Exodus From American Labs

Wan Fengyi and the Quiet Exodus From American Labs

Cancer researcher Wan Fengyi has left the United States after more than two decades in American academic labs to take up a chair professorship at China's Zhejiang University, anchoring his work in a national laboratory tied to its Second Affiliated Hospital. His move in October 2026 marks another high-profile return of seasoned biomedical talent from U.S. institutions to major Chinese research hubs.

At first glance, a headline about a professor changing universities reads like routine academic churn. It is not. Wan spent more than twenty years building a body of work across American biomedical centers, including appointments tied to the Johns Hopkins Bloomberg School of Public Health and the Sidney Kimmel Comprehensive Cancer Center. Losing an established principal investigator who studies how microbes, inflammation, and cellular signaling intersect with colorectal cancer removes years of institutional memory and specialized experimental momentum from the U.S. ecosystem.

Headline summaries usually stop at "scientist returns home" and call it a day. That framing misses the real mechanics driving late-career relocations in biomedical science. Principal investigators rarely pack up a lab over a single email or a minor pay bump. They weigh multi-year grant predictability, animal model and clinical sample access, administrative friction, geopolitical scrutiny, and the sheer speed at which a host institution can stand up infrastructure.

Why Established Principal Investigators Actually Move

Early-career postdocs chase prestige and publication volume. Mid- and late-career principal investigators chase runway.

In the U.S. academic system, running a wet lab studying host-pathogen interactions and tumorigenesis is an exercise in perpetual fundraising. Even strong investigators spend an enormous share of their calendar writing and revising grant proposals, navigating federal review cycles, and managing budgets that can tighten mid-stream. When a lab relies on long-horizon mechanistic experiments—tracking how specific gut microbes alter epithelial cells or drive inflammatory cascades—short grant cycles create real operational drag.

Chinese research universities have spent the past decade learning from that pain point. Rather than offering only a modest salary increase, top institutions like Zhejiang University compete with chair professorships, dedicated laboratory footprints, streamlined startup packages, and close integration with large affiliated hospitals. A hospital-linked national laboratory gives a basic and translational researcher something many standalone university departments struggle to match at scale: direct proximity to clinical specimens, patient cohorts, and hospital-based oncology teams.

Wan's departure also did not happen in isolation. Over the same window in 2026, Zhejiang University brought in multiple prominent recruits from U.S. institutions—including former U.S. National Institutes of Health investigator Kai Ge joining its First Affiliated Hospital in May to establish an epigenetics institute. Across Asia more broadly, major research universities in Singapore and Hong Kong have similarly landed senior scientists who spent decades at American institutions.

A single recruitment is a career story. A cluster of senior departures over two decades of U.S. tenure is a structural signal about where institutional energy and capital are concentrating.

Critics in Washington and on U.S. campuses often attribute these moves solely to targeted recruitment programs or geopolitical pull. That explanation is incomplete. Push factors inside American academia matter just as much—hyper-competitive grant paylines, rising compliance overhead, lab space bottlenecks, and a climate in which international collaborations face heightened suspicion. When pull and push align, seasoned scientists with global networks decide whether the next ten years of their scientific life will be easier to build elsewhere.

The Science Behind Microbes and Colorectal Cancer

To understand what a recruitment like Wan's means for oncology, it helps to look at the biology he has investigated. Colorectal cancer has long been viewed primarily through a genetic lens—accumulated mutations in oncogenes and tumor suppressors driving cells out of control. Over the past two decades, cancer biology has broadened to treat the tumor microenvironment and the gut microbiome as active co-conspirators rather than passive background noise.

Certain bacteria living in or passing through the lower gastrointestinal tract do not merely sit alongside colonic tissue. Some produce toxins or trigger chronic inflammatory pathways—such as NF-κB signaling—that stress cells, damage DNA, or reshape local immune responses. Research in this space has examined links between gastrointestinal pathogens, bacterial toxins, and colonic tumorigenesis in experimental models and patient-derived samples.

From Inflammation to Tumorigenesis

Chronic inflammation in the colon is a well-documented risk factor for malignant transformation. When immune cells and epithelial cells stay locked in a prolonged inflammatory state, signaling cascades meant to clear microbes or repair tissue can inadvertently promote cell proliferation and survival.

Researchers studying these pathways look at how specific microbial factors interact with host receptors and intracellular signaling complexes. In simplified terms, if a microbe nudges inflammatory switches into overdrive while weakening normal epithelial safeguards, the local tissue environment becomes far more hospitable to precancerous changes.

Why Translating Microbiome Findings Is Hard

Translating microbiome and signaling discoveries into approved cancer therapies is notoriously messy. Unlike a clean small-molecule kinase inhibitor aimed at a single mutated protein, the gut is a crowded, shifting ecosystem.

  • Strain variation matters: Two strains of the same bacterial species can behave very differently in a host depending on whether they produce specific toxins or virulence factors.
  • Host context shifts outcomes: Diet, baseline microbiota, genetics, and prior antibiotic exposure all change how a person's immune system responds to a given microbe.
  • Causation requires care: Showing a microbe is enriched near a tumor is not the same as proving it initiated the cancer, which is why controlled animal models and mechanistic cell assays are essential.

Because of that complexity, progress depends on patient, painstaking bench work paired with clinical insight. Moving a lab across oceans while keeping those experimental lines running requires serious logistical support.

Hospital Integration and the Translational Gap

One of the quieter advantages embedded in Wan's move is his placement within a national laboratory connected to Zhejiang University's Second Affiliated Hospital. In academic medicine worldwide, the gap between a compelling finding in mice or cell culture and a validated clinical strategy in patients remains wide.

Large teaching hospitals in China possess massive patient volumes, which can accelerate sample collection and clinical correlation when governance and ethics standards are rigorously applied. At the same time, high patient volume alone does not guarantee better science. Good translational research still depends on rigorous experimental controls, reproducible data, open peer scrutiny, and careful clinical trial design.

(Hypothetical example: Suppose a laboratory identifies a microbial toxin that accelerates inflammatory signaling in colon tissue. Turning that observation into a screening marker or therapeutic strategy requires validating the signal across independent patient cohorts, confirming assay reproducibility across labs, and testing whether modifying the pathway actually changes clinical outcomes rather than just altering biomarkers.)

That reality check cuts both ways. Moving to a well-funded hospital-affiliated institute can speed up access to resources and collaborators, yet the scientific hurdles of colorectal cancer biology do not vanish at the border. Biology remains stubborn regardless of which country funds the pipette tips.

What This Shift Means for Global Cancer Research

Global biomedical science has never been a closed loop, even when political rhetoric treats it like one. Cancer research advances through shared reagents, published datasets, international conferences, and training pipelines that cross borders constantly.

When experienced investigators relocate from the U.S. to China—or move in the opposite direction—the immediate effect is a redistribution of mentorship and project leadership. Junior researchers, graduate students, and visiting fellows naturally gravitate toward labs with strong funding, active publication records, and clear experimental momentum. Over time, those choices shape which scientific questions get answered first and where the next generation of leaders trains.

For American institutions, the lesson is straightforward even if the fixes are hard. Retaining mid- and late-career talent requires more than appeals to tradition. It demands competitive research infrastructure, predictable funding mechanisms, manageable administrative burdens, and an environment where scientists can pursue ambitious, multi-year questions without constant friction.

For China's top universities, recruiting overseas veterans solves only part of the equation. Long-term scientific leadership depends not just on landing prominent returnees, but on sustaining day-to-day research culture, independent inquiry, and durable international exchange once the initial recruitment fanfare fades. Watch where the next wave of grant renewals, clinical collaborations, and junior trainees goes over the next three years—that is where the real balance of scientific momentum will show.

JH

Jun Harris

Jun Harris is a meticulous researcher and eloquent writer, recognized for delivering accurate, insightful content that keeps readers coming back.